These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 26631873)

  • 1. Detection of Circulating BRAF(V600E) in Patients with Papillary Thyroid Carcinoma.
    Lubitz CC; Parangi S; Holm TM; Bernasconi MJ; Schalck AP; Suh H; Economopoulos KP; Gunda V; Donovan SE; Sadow PM; Wirth LJ; Sullivan RJ; Panka DJ
    J Mol Diagn; 2016 Jan; 18(1):100-8. PubMed ID: 26631873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating BRAF
    Lubitz CC; Zhan T; Gunda V; Amin S; Gigliotti BJ; Fingeret AL; Holm TM; Wachtel H; Sadow PM; Wirth LJ; Sullivan RJ; Panka DJ; Parangi S
    Thyroid; 2018 Mar; 28(3):328-339. PubMed ID: 29378474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of BRAF c.1799T > A (p.V600E) mutation using residual routine fine-needle aspiration specimens of papillary thyroid carcinoma.
    Zhao H; Zhang ZH; Zhou B; Xiao T; Pan QJ; Guo HQ
    Diagn Cytopathol; 2015 Oct; 43(10):786-90. PubMed ID: 26152656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of peripheral BRAF(V600E) mutation as a possible novel marker for papillary thyroid carcinomas.
    Kwak JY; Jeong JJ; Kang SW; Park S; Choi JR; Park SJ; Kim EK; Chung WY
    Head Neck; 2013 Nov; 35(11):1630-3. PubMed ID: 23161556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma.
    Jung YY; Yoo JH; Park ES; Kim MK; Lee TJ; Cho BY; Chung YJ; Kang KH; Ahn HY; Kim HS
    Pathol Res Pract; 2015 Feb; 211(2):162-70. PubMed ID: 25468810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating BRAFV600E in the diagnosis and follow-up of differentiated papillary thyroid carcinoma.
    Pupilli C; Pinzani P; Salvianti F; Fibbi B; Rossi M; Petrone L; Perigli G; De Feo ML; Vezzosi V; Pazzagli M; Orlando C; Forti G
    J Clin Endocrinol Metab; 2013 Aug; 98(8):3359-65. PubMed ID: 23788690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma.
    Sun J; Zhang J; Lu J; Gao J; Lu T; Ren X; Duan H; Liang Z
    Int J Clin Exp Pathol; 2015; 8(11):15072-8. PubMed ID: 26823846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined effect of Hashimoto's thyroiditis and BRAF(V600E) mutation status on aggressiveness in papillary thyroid cancer.
    Kim SJ; Myong JP; Jee HG; Chai YJ; Choi JY; Min HS; Lee KE; Youn YK
    Head Neck; 2016 Jan; 38(1):95-101. PubMed ID: 25213729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas.
    Kim BH; Kim IJ; Lee BJ; Lee JC; Kim IS; Kim SJ; Kim WJ; Jeon YK; Kim SS; Kim YK
    Yonsei Med J; 2015 May; 56(3):634-40. PubMed ID: 25837167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
    Gouveia C; Can NT; Bostrom A; Grenert JP; van Zante A; Orloff LA
    JAMA Otolaryngol Head Neck Surg; 2013 Nov; 139(11):1164-70. PubMed ID: 24030686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma.
    Zhu X; Luo Y; Bai Q; Lu Y; Lu Y; Wu L; Zhou X
    Exp Mol Pathol; 2016 Feb; 100(1):236-41. PubMed ID: 26795218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The BRAF(V600E) mutation influences the short- and medium-term outcomes of classic papillary thyroid cancer, but is not an independent predictor of unfavorable outcome.
    Russo M; Malandrino P; Nicolosi ML; Manusia M; Marturano I; Trovato MA; Pellegriti G; Frasca F; Vigneri R
    Thyroid; 2014 Aug; 24(8):1267-74. PubMed ID: 24787545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF(V600E) Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer.
    Fraser S; Go C; Aniss A; Sidhu S; Delbridge L; Learoyd D; Clifton-Bligh R; Tacon L; Tsang V; Robinson B; Gill AJ; Sywak M
    World J Surg; 2016 Jul; 40(7):1618-24. PubMed ID: 27138882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
    Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
    Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The expression profile of integrin receptors and osteopontin in thyroid malignancies varies depending on the tumor progression rate and presence of BRAF V600E mutation.
    Chernaya G; Mikhno N; Khabalova T; Svyatchenko S; Mostovich L; Shevchenko S; Gulyaeva L
    Surg Oncol; 2018 Dec; 27(4):702-708. PubMed ID: 30449496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma.
    Givens DJ; Buchmann LO; Agarwal AM; Grimmer JF; Hunt JP
    Laryngoscope; 2014 Sep; 124(9):E389-93. PubMed ID: 24604709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationships of BRAF mutation and HMGB1 to papillary thyroid carcinoma.
    Guan X; Wang P; Chi J; Zhao S; Wang F
    Biochem Biophys Res Commun; 2017 May; 486(4):898-903. PubMed ID: 28342873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
    Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L
    Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma.
    Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
    Surgery; 2015 Dec; 158(6):1500-11. PubMed ID: 26120069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of BRAF mutation detection in fine-needle aspiration biopsy samples read as "suspicious for papillary thyroid carcinoma".
    Jara SM; Bhatnagar R; Guan H; Gocke CD; Ali SZ; Tufano RP
    Head Neck; 2015 Dec; 37(12):1788-93. PubMed ID: 24989827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.